Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Eli Lilly CDR (CAD Hedged)

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Phase 2

Recruiting

Conditions: Ulcerative Colitis
Ulcerative Colitis Chronic

Interventions: Drug: Eltrekibart
Drug: Placebo
Drug: Mirikizumab

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 140

Registration Number: NCT06598943

Locations: 🇺🇸
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸
Southern California GI and Liver Centers (SCLC), Coronado, California, United States
🇺🇸
Om Research, LLC, Lancaster, California, United States

and more 180 locations

A Study of LY4065967 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY4065967
Drug: Placebo
Drug: Rosuvastatin

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 59

Registration Number: NCT06594159

Locations: 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Phase 3

Active, not recruiting

Conditions: Psoriasis
Obesity

Interventions: Drug: Ixekizumab
Drug: Tirzepatide

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT06588283

Locations: 🇺🇸
Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology, Birmingham, Alabama, United States
🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States

and more 69 locations

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Non-small Cell Lung Cancer
Colorectal Cancer

Interventions: Drug: LY3962673
Drug: Cetuximab
Drug: Gemcitabine
Drug: nab-paclitaxel
Drug: Oxaliplatin
Drug: leucovorin
Drug: Irinotecan
Drug: 5-fluorouracil

First Posted Date: 2024-09-19

Last Posted Date: 2025-07-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 570

Registration Number: NCT06586515

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States

and more 49 locations

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Phase 3

Active, not recruiting

Conditions: Psoriatic Arthritis
Obesity

Interventions: Drug: Ixekizumab
Drug: Tirzepatide

First Posted Date: 2024-09-19

Last Posted Date: 2025-07-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT06588296

Locations: 🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler, Chandler, Arizona, United States
🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff, Arizona, United States

and more 81 locations

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Orforglipron
Drug: Placebo

First Posted Date: 2024-09-05

Last Posted Date: 2025-04-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 300

Registration Number: NCT06584916

Locations: 🇺🇸
Cahaba Research, Birmingham, Alabama, United States
🇺🇸
Cahaba Research - Pelham, Pelham, Alabama, United States
🇺🇸
Southern California Dermatology, Inc., Santa Ana, California, United States

and more 26 locations

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Phase 2

Recruiting

Conditions: Neuropathic Pain
Distal Sensory Polyneuropathy

Interventions: Drug: LY3848575
Drug: Placebo

First Posted Date: 2024-08-23

Last Posted Date: 2025-06-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 450

Registration Number: NCT06568042

Locations: 🇺🇸
MD First Research - Chandler, Chandler, Arizona, United States
🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸
Neuro-Pain Medical Center, Fresno, California, United States

and more 78 locations

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Recruiting

Conditions: Alzheimer Disease

Interventions: Drug: Donanemab
Drug: Usual Care

First Posted Date: 2024-08-22

Last Posted Date: 2025-02-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 3060

Registration Number: NCT06566170

Locations: 🇺🇸
Rehabilitation & Neurological Services, Huntsville, Alabama, United States

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Solid Tumor
SMARCA4-Deficient Tumor
Advanced Solid Tumor
Non-small Cell Lung Cancer

Interventions: Drug: LY4050784
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Nab paclitaxel

First Posted Date: 2024-08-20

Last Posted Date: 2025-05-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 340

Registration Number: NCT06561685

Locations: 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸
University of Colorado Health Hospital, Aurora, Colorado, United States
🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States

and more 19 locations

A Study of LY3532226 in Participants With Obesity

Phase 1

Active, not recruiting

Conditions: Obesity

Interventions: Drug: LY3532226
Drug: Placebo

First Posted Date: 2024-08-16

Last Posted Date: 2025-06-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 129

Registration Number: NCT06557356

Locations: 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy